about
Targeted drugs and Psycho-oncological intervention for breast cancer patientsTargeted therapy for HER2 positive breast cancerManagement of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment optionsUnderstanding breast cancer stem cell heterogeneity: time to move on to a new research paradigmTargeted therapy for hepatocellular carcinoma: novel agents on the horizonMetastatic colonization by circulating tumour cellsInsulin-like growth factor system in cancer: novel targeted therapiesMetabolomic profiling of hormone-dependent cancers: a bird's eye viewHER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerTumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancerAltering calcium influx for selective destruction of breast tumorActive kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancerSingle-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancerPerspectives of breast cancer thermotherapies.Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancerBasal but not luminal mammary epithelial cells require PI3K/mTOR signaling for Ras-driven overgrowth.The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment responseViola tricolor induces apoptosis in cancer cells and exhibits antiangiogenic activity on chicken chorioallantoic membraneThe p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.Comparison of cantharidin toxicity in breast cancer cells to two common chemotherapeuticsTaspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transitionLoss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation.Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenograftsTumorspheres but not adherent cells derived from retinoblastoma tumors are of malignant origin.Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome.Therapeutic potential of ERK5 targeting in triple negative breast cancerTumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.Combining functional genomics strategies identifies modular heterogeneity of breast cancer intrinsic subtypesHES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer
P2860
Q26748919-6336885D-2946-49CA-A2C8-C1C205274887Q26830496-F520A17F-9596-4E5F-9DF2-B6072F5CD2EAQ26995549-698C6B8D-EC29-452B-91C2-4DDFADB72BA8Q26999684-C58E2C03-486B-40AF-BB68-76B32682A2A7Q27002288-7538AB8A-E9B8-4431-AC34-285F9069E9C0Q28076164-632C9AF1-5C5F-41A5-A0B0-479A980F0FA1Q28081603-22E85497-6BEC-4883-A2E1-270F4FE6DCEFQ28084834-EBB5B590-43D9-4135-B993-EBC066294BE6Q28085413-A298369B-1762-44C0-BB98-3ED969FD0D65Q28483867-67C87E08-A248-4E6B-BB5F-6F8FB829FF52Q29248555-F522CECE-89F8-4782-B4B1-EF287739FC1DQ30582030-479C5D03-F369-4928-895E-417EBA81DBDCQ33587482-C15049C1-FE8B-458F-8AFA-A50F25889EFAQ33654352-ECB0DA86-6B88-415D-8EB7-FAF48BC810C6Q33668653-0652609D-F813-4102-8BC0-FA253DAD01C7Q33738675-D892D56B-54FC-4922-998E-311EDC175B34Q33739313-87A79831-D2A8-4B0B-8A93-A164E78EC7B2Q33789409-357943AA-E2A5-48EE-B212-722BFE0BA846Q33812500-E1807700-E8C7-46F2-A014-46C4A4671E2EQ33832727-381942AE-4B88-42C9-86A3-067F24C48149Q33903662-E78266EA-6A2E-48BD-8512-CAB8104B0062Q33913901-67560546-B593-4AAB-969A-EB43E69D60D6Q34016480-D155452D-5601-4480-88FE-582AC85E1156Q34051930-7A914B04-1898-4669-B9BB-DD8C4CF6D1C8Q34177213-D81B5E3C-BF30-46A5-A998-A2AB915B9BD3Q34212168-9EDB500D-BAA1-4D2B-8CC3-6C24D06C5E3AQ34267632-6702965F-EFAF-4D40-88D0-44DBD7FF627FQ34452426-1344F568-BFE1-49D7-9D93-0E78FEBD5672Q34522228-3A4E2E76-A509-4FA5-AF08-5A4D1D66C758Q34619329-C7E7B7B3-405E-4F5F-9EB9-CD0F0B366E65Q34638020-C1631F08-D169-48B9-9F69-83809AB80706Q34714574-FE9817D2-563E-4B81-B6AC-9CB519881FABQ34795615-2A823156-AAB8-4319-B226-51D604BA36BFQ34815370-A36D1EAA-64EB-4CE9-9D4B-4092BD61BAB9Q34956816-0B1ABE5C-65C6-482E-A1D1-99CFF3EC113DQ35050560-8E733839-0004-4C44-934B-C3EF6760BE74Q35149532-850B4768-6432-4902-9C1C-343B29EAD826Q35181168-07ED486B-BD51-4029-833E-43841BC19D21Q35411077-88A158B2-C419-428A-BECE-2766A0CB217CQ35434433-A756F7F4-800E-4FF6-B8F1-A341487F6BDF
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Targeted therapies for breast cancer.
@ast
Targeted therapies for breast cancer.
@en
type
label
Targeted therapies for breast cancer.
@ast
Targeted therapies for breast cancer.
@en
prefLabel
Targeted therapies for breast cancer.
@ast
Targeted therapies for breast cancer.
@en
P2860
P356
P1476
Targeted therapies for breast cancer.
@en
P2093
José Baselga
Michaela J Higgins
P2860
P304
P356
10.1172/JCI57152
P407
P577
2011-10-03T00:00:00Z